BIIB - Biogen Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—General
Cambridge,
United States
Type: Equity
BIIB price evolution
BIIB
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1908.9 | $1074.4 | $1049.9 | |
| Short term investments | ||||
| Net receivables | $1988.1 | $2078.2 | $1999.7 | $2100 |
| Inventory | $2469.2 | $2506.1 | $2516.8 | $2527.4 |
| Total current assets | $6830.5 | $7108.5 | $6756.2 | $6859.3 |
| Long term investments | $681.5 | $697.6 | $745 | |
| Property, plant & equipment | $3591.3 | $3638.7 | $3703.4 | $3729.7 |
| Goodwill & intangible assets | $14460.3 | $14512.1 | $14582.2 | |
| Total noncurrent assets | $19695.6 | $19811.4 | $19985.5 | |
| Total investments | $681.5 | $697.6 | $745 | |
| Total assets | $28313.2 | $26804.1 | $26567.6 | $26844.8 |
| Current liabilities | ||||
| Accounts payable | $422.7 | $354.5 | $387 | $403.3 |
| Deferred revenue | ||||
| Short long term debt | $250 | $150 | ||
| Total current liabilities | $5425 | $3108.2 | $3222.8 | $3434.3 |
| Long term debt | $4545.8 | $6659.5 | $6696.6 | $7188.2 |
| Total noncurrent liabilities | $7806.8 | $8131.8 | $8611.1 | |
| Total debt | $6659.5 | $6946.6 | $7338.2 | |
| Total liabilities | $11954.3 | $10915 | $11354.6 | $12045.4 |
| Shareholders' equity | ||||
| Retained earnings | $18993.1 | $18604.6 | $18021 | $17627.6 |
| Other shareholder equity | -$145.7 | -$146 | -$160.5 | -$153.7 |
| Total shareholder equity | $15889.1 | $15213 | $14799.4 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1049.9 | $3419.3 | $2261.4 | $1331.2 |
| Short term investments | $1473.5 | $1541.1 | $1278.9 | |
| Net receivables | $2100 | $2136.4 | $1961.7 | $2327.3 |
| Inventory | $2527.4 | $1344.4 | $1351.5 | $1068.6 |
| Total current assets | $6859.3 | $9791.2 | $7856.5 | $6887.1 |
| Long term investments | $745 | $2234.9 | $2831.5 | $3671.1 |
| Property, plant & equipment | $3729.7 | $3702.5 | $3791.8 | $3844.8 |
| Goodwill & intangible assets | $14582.2 | $7599.1 | $7982.4 | $8846.4 |
| Total noncurrent assets | $19985.5 | $14762.9 | $16020.8 | $17731.8 |
| Total investments | $745 | $3708.4 | $4372.6 | $4950 |
| Total assets | $26844.8 | $24554.1 | $23877.3 | $24618.9 |
| Current liabilities | ||||
| Accounts payable | $403.3 | $491.5 | $589.2 | $454.9 |
| Deferred revenue | ||||
| Short long term debt | $150 | $999.1 | ||
| Total current liabilities | $3434.3 | $3272.8 | $4298.2 | $3742.2 |
| Long term debt | $7188.2 | $6281 | $6604.4 | $7828.2 |
| Total noncurrent liabilities | $8611.1 | $7892.9 | $8619.4 | $10190.6 |
| Total debt | $7338.2 | $6614 | $7603.5 | $7828.2 |
| Total liabilities | $12045.4 | $11156.2 | $12917.6 | $13932.8 |
| Shareholders' equity | ||||
| Retained earnings | $17627.6 | $16466.5 | $13911.7 | $13976.3 |
| Other shareholder equity | -$153.7 | -$149.2 | -$106.7 | -$299 |
| Total shareholder equity | $14799.4 | $13397.9 | $10896.2 | $10700.3 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2465.8 | $2290.5 | $2386.3 | |
| Cost of revenue | $542.2 | $618.3 | ||
| Gross Profit | $1827.1 | $1748.3 | $1768 | |
| Operating activities | ||||
| Research & development | $452.9 | $570.9 | ||
| Selling, general & administrative | $581.5 | $608.5 | ||
| Total operating expenses | $1268.1 | $1283.5 | $1476.4 | |
| Operating income | $464.8 | $291.6 | ||
| Income from continuing operations | ||||
| EBIT | $464.8 | $292.4 | ||
| Income tax expense | $62.5 | $71.4 | $42.7 | |
| Interest expense | -$83.3 | |||
| Net income | ||||
| Net income | $388.5 | $393.4 | $249.7 | |
| Income (for common shares) | $393.4 | $249.7 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9835.6 | $10173.4 | $10981.7 | $13444.6 |
| Cost of revenue | $2533.4 | $2278.3 | $2109.7 | $1805.2 |
| Gross Profit | $7302.2 | $7895.1 | $8872 | $11639.4 |
| Operating activities | ||||
| Research & development | $2462 | $2231.1 | $2501.2 | $3990.9 |
| Selling, general & administrative | $2549.7 | $2403.6 | $2674.3 | $2504.5 |
| Total operating expenses | $6005.4 | $4303.3 | $6031.3 | $7089.3 |
| Operating income | $1296.8 | $3591.8 | $2840.7 | $4550.1 |
| Income from continuing operations | ||||
| EBIT | $1296.4 | $3679.7 | $1608.6 | $4992.9 |
| Income tax expense | $135.3 | $632.8 | $52.5 | $992.3 |
| Interest expense | ||||
| Net income | ||||
| Net income | $1161.1 | $3046.9 | $1556.1 | $4000.6 |
| Income (for common shares) | $1161.1 | $3046.9 | $1556.1 | $4000.6 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $583.6 | $393.4 | $249.7 | |
| Operating activities | ||||
| Depreciation | $158.9 | $147.5 | $140.1 | |
| Business acquisitions & disposals | $406.8 | -$590.5 | ||
| Stock-based compensation | $70.6 | $72.8 | $54.9 | |
| Total cash flows from operations | $625.8 | $553.2 | $12.5 | |
| Investing activities | ||||
| Capital expenditures | $60.4 | -$120.9 | -$65.2 | |
| Investments | $1.9 | $55.6 | $13.4 | |
| Total cash flows from investing | -$780.6 | $466.5 | -$66 | -$652.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$250 | -$400 | -$650 | |
| Total cash flows from financing | -$691.4 | -$245.2 | -$439.6 | -$646.1 |
| Effect of exchange rate | $6.7 | -$12.6 | -$23.1 | $47.9 |
| Change in cash and equivalents | $649.3 | $847.1 | $47.6 | -$1285.9 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1161.1 | $3046.9 | $1556.1 | $4000.6 |
| Operating activities | ||||
| Depreciation | $494.8 | $638 | $1117 | $666.9 |
| Business acquisitions & disposals | -$6138 | $990.3 | $28.1 | -$1006.5 |
| Stock-based compensation | $264.2 | $254.1 | $238.6 | $198.3 |
| Total cash flows from operations | $1547.2 | $1384.3 | $3639.9 | $4229.8 |
| Investing activities | ||||
| Capital expenditures | -$311.4 | $339.4 | -$276.9 | -$476.8 |
| Investments | $2359.7 | $222.5 | -$309.8 | $976.6 |
| Total cash flows from investing | -$4101 | $1576.6 | -$563.7 | -$608.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$750 | -$1800 | -$6679.1 | |
| Net borrowings | $187.3 | -$1002.2 | -$170 | $1467.4 |
| Total cash flows from financing | $149.3 | -$1747.3 | -$2086.2 | -$5272.7 |
| Effect of exchange rate | $35.1 | -$55.7 | -$59.8 | $69 |
| Change in cash and equivalents | -$2404.5 | $1213.6 | $990 | -$1651.5 |
News
Fundamentals
| Market cap | $19.90B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 144.90M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -2.55% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.81 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.26 |
| Quick ratio | 0.80 |